BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
rs6983267
,
PDX1
,
Coagulation
,
Leukemia
,
Leukocyte
,
Metabolism of nitric oxide
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
Raf-like Ras-binding
(biogroup)
Summary
General Info
Body Atlas
Most Correlated Tissues
Adrenal gland cortex
Omental adipose tissue
Putamen
Pericardium
Small intestine
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Cardio-facio-cutaneous syndrome
Injury of external ear
Cryptococcosis
Lentigo
Peritoneal foreign body
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
GSK-3-inhibitor-II
Tie2 kinase inhibitor
CGP 60474
UNC1215
PHA 793887
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
ADAMTS9
RNPC3
TMEFF2
SYNE2
MN1
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
L1000 CMAP - Breast cancer MCF7.101 cells with CRISPR targeted gene knockouts
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
L1000 CMAP - Breast carcinoma BT20 cells treated with small molecule perturbagens
L1000 CMAP - Neural progenitor NPC cells treated with small molecule perturbagens
Explore Curated Studies Results
Literature
Most Relevant Literature
There were no matches for Raf-like Ras-binding
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML
Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advan…
BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer
New Individualized Therapy Trial for Metastatic Colorectal Cancer
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ